Adjunctive Use of Apyrase to Fibrinolytic Therapy

$226,120R43FY2009HLNIH

Apt Therapeutics, Inc., Saint Louis MO

Investigators

Linked publications & trials

Paper 39649580 Paper 39606375 Paper 39596582 Paper 39574859 Paper 39556651 Paper 39554199 Paper 39501071 Paper 39497627 Paper 39453822 Paper 39439386 Paper 39399015 Paper 39398280 Paper 39354197 Paper 39316596 Paper 39316441 Paper 39314973 Paper 39288206 Paper 39281736 Paper 39267982 Paper 39179143 Paper 39148837 Paper 39132475 Paper 39087344 Paper 39073889 Paper 39041933 Paper 39034892 Paper 39004643 Paper 38997435 Paper 38974693 Paper 38947043 Paper 38889215 Paper 38795337 Paper 38753617 Paper 38747708 Paper 38747290 Paper 38725587 Paper 38716661 Paper 38703940 Paper 38699369 Paper 38699335 Paper 38664073 Paper 38656975 Paper 38652672 Paper 38643925 Paper 38635767 Paper 38627022 Paper 38585741 Paper 38577266 Paper 38571307 Paper 38559110 Paper 38552474 Paper 38551823 Paper 38530665 Paper 38499766 Paper 38478997 Paper 38464320 Paper 38464146 Paper 38456289 Paper 38451190 Paper 38432335 Paper 38410430 Paper 38381480 Paper 38372177 Paper 38370803 Paper 38355559 Paper 38343816 Paper 38335160 Paper 38323698 Paper 38313294 Paper 38309426 Paper 38293196 Paper 38270904 Paper 38226871 Paper 38194040 Paper 38190104 Paper 38168159 Paper 38159634 Paper 38105971 Paper 38099473 Paper 38097206 Paper 38070817 Paper 38048800 Paper 38029852 Paper 37982128 Paper 37943208 Paper 37940398 Paper 37940004 Paper 37935687 Paper 37934796 Paper 37916841 Paper 37874814 Paper 37873226 Paper 37850400 Paper 37848499 Paper 37828734 Paper 37795703 Paper 37790448 Paper 37786380 Paper 37777527 Paper 37709864

Abstract

DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for treatment of acute myocardial infarction. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. Using a protein informatics approach, we have successfully engineered human apyrases which exhibit both antiplatelet and anti-inflammatory activities. With the Phase I grant support, we will determine whether optimized human apyrases, in combination with tPA, induce rapid and sustained coronary artery recanalization without increasing bleeding risk. PUBLIC HEALTH RELEVANCE: We will utilize a coronary thrombotic model in dogs to validate whether human apyrase more effectively improve coronary patency than clopidogrel without increasing bleeding risk.

View original record on NIH RePORTER →